Jenburkt Pharma Q2 FY27: revenue Rs 4,831.82 lakh, PAT Rs 1,020.94 lakh
Jenburkt Pharmaceuticals’ standalone Q2 FY27 revenue was Rs 4,831.82 lakh and PAT Rs 1,020.94 lakh, versus Rs 4,555.76 lakh and Rs 1,016.34 lakh a year earlier.
Key takeaways
- Revenue from operations Rs 4,831.82 lakh vs Rs 4,555.76 lakh a year earlier
- Total income Rs 5,057.08 lakh vs Rs 4,763.66 lakh in the corresponding quarter
- Total expenses Rs 3,623.13 lakh vs Rs 3,330.46 lakh in the year-ago quarter
- Profit before tax Rs 1,433.95 lakh vs Rs 1,433.20 lakh a year earlier
- PAT Rs 1,020.94 lakh vs Rs 1,016.34 lakh; EPS Rs 23.13 vs Rs 23.03
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 4,831.82 lakh | Rs 4,555.76 lakh | +6.1% |
| PAT | Rs 1,020.94 lakh | Rs 1,016.34 lakh | +0.5% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 21.13% of revenue, down 117 bps from 22.31%.
- Total expenses rose 8.8% while revenue rose 6.1%.
• Revenue from operations (quarter ended 30-09-2026): Rs 4,831.82 lakh vs Rs 4,555.76 lakh in the quarter ended 30-09-2025
• Other income: Rs 225.26 lakh vs Rs 207.90 lakh
• Total income: Rs 5,057.08 lakh vs Rs 4,763.66 lakh
• Total expenses: Rs 3,623.13 lakh vs Rs 3,330.46 lakh
• Cost of materials consumed: Rs 195.65 lakh vs Rs 219.35 lakh
• Purchase of stock-in-trade: Rs 719.96 lakh vs Rs 628.33 lakh
• Changes in inventories of finished goods, stock-in-trade and WIP: Rs 79.01 lakh vs Rs -12.04 lakh
• Employee benefit expenses: Rs 1,487.44 lakh vs Rs 1,393.25 lakh
• Finance costs: Rs 12.97 lakh vs Rs 10.74 lakh
• Depreciation and amortisation expense: Rs 79.89 lakh vs Rs 74.39 lakh
• Other expenses: Rs 1,048.21 lakh vs Rs 1,016.44 lakh
• Profit before exceptional items and tax: Rs 1,433.95 lakh vs Rs 1,433.20 lakh
• Exceptional items (Impact of Labour Codes #): Rs 0.00 lakh vs Rs 0.00 lakh
• Profit before tax: Rs 1,433.95 lakh vs Rs 1,433.20 lakh
• Current tax: Rs 350.00 lakh vs Rs 400.00 lakh
• Income tax for previous years: Rs 0.00 lakh vs Rs 0.00 lakh
• Deferred tax: Rs 63.01 lakh vs Rs 16.86 lakh
• Profit/(Loss) after tax: Rs 1,020.94 lakh vs Rs 1,016.34 lakh
• Total comprehensive income for the period: Rs 964.08 lakh vs Rs 988.21 lakh
• Paid up equity share capital (F.V. Rs.10/- each): Rs 441.33 lakh vs Rs 441.33 lakh
• Earnings per share (in Rs.) (F.V. Rs.10/-) Basic and Diluted: Rs 23.13 vs Rs 23.03
According to the statement of standalone unaudited financial results for the quarter ended 30-09-2026, revenue from operations rose to Rs 4,831.82 lakh from Rs 4,555.76 lakh in the corresponding quarter ended 30-09-2025. Other income also increased to Rs 225.26 lakh from Rs 207.90 lakh, taking total income to Rs 5,057.08 lakh versus Rs 4,763.66 lakh a year earlier.
Total expenses for the quarter were Rs 3,623.13 lakh compared with Rs 3,330.46 lakh in the same quarter last year. Within this, cost of materials consumed was Rs 195.65 lakh (vs Rs 219.35 lakh), purchase of stock-in-trade was Rs 719.96 lakh (vs Rs 628.33 lakh), and changes in inventories of finished goods, stock-in-trade and WIP moved to Rs 79.01 lakh from Rs -12.04 lakh. Employee benefit expenses increased to Rs 1,487.44 lakh from Rs 1,393.25 lakh, finance costs were Rs 12.97 lakh vs Rs 10.74 lakh, depreciation and amortisation expense was Rs 79.89 lakh vs Rs 74.39 lakh, and other expenses were Rs 1,048.21 lakh vs Rs 1,016.44 lakh.
Profit before exceptional items and tax stood at Rs 1,433.95 lakh, broadly in line with Rs 1,433.20 lakh in the corresponding quarter. There were no exceptional items related to the Impact of Labour Codes in either quarter (Rs 0.00 lakh in both periods), so profit before tax was also Rs 1,433.95 lakh vs Rs 1,433.20 lakh. After current tax of Rs 350.00 lakh (vs Rs 400.00 lakh), no income tax for previous years (Rs 0.00 lakh in both periods) and deferred tax of Rs 63.01 lakh (vs Rs 16.86 lakh), profit after tax came in at Rs 1,020.94 lakh compared with Rs 1,016.34 lakh a year earlier.
Total comprehensive income for the quarter was Rs 964.08 lakh versus Rs 988.21 lakh in the corresponding quarter. Paid up equity share capital remained Rs 441.33 lakh in both periods, and basic and diluted earnings per share (face value Rs 10) were Rs 23.13 compared with Rs 23.03 in the same quarter last year.
Get Jenburkt Pharmaceuticals Ltd's next results the minute they're filed
Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.
- We'll start you off following JENBURPH.
- 14 days free, no card. After that you keep a free account.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.